Verification of non-heritable retinoblastoma in patients with unilateral disease requires either the detection of both somatic RB1 pathogenic variants and the exclusion of those variants in a peripheral blood sample [9] or, in very rare cases, the identification of somatic MYCN amplification [5]. Here, RB1 is linked to retinoblastoma.